Kairos Pharma Amends Helena ELOC Pricing and Extends Option to 2028
Kairos Pharma amended its Helena equity line: 97% of average daily VWAP pricing, a one-day pricing period and an option extended to December 2028.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Kairos Pharma disclosed three amendments to its equity line of credit with Helena Global Investment Opportunities I, according to TradingView, which cites filings with the SEC. The purchase price will now be 97% of the average daily volume-weighted average price (VWAP). The pricing period has been cut from three trading days to one.
The company's option to use this financing has also been extended through December 31, 2028.
why it matters
The amendments change how the shares are priced and how long the financing arrangement stays available, though the size of the facility is not stated in the documents. Equity lines of this type typically imply possible issuance of new shares, so investors watch the pricing terms closely. For the broader market, the news is routine.
tags
instruments
sources
- Kairos Pharma Updates Helena ELOC Pricing and Extends Option Through 2028 — TradingView, 3 November 2026 at 16:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗